Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew P. Goetz; Katrin Sangkuhl; Henk Jan Guchelaar; Matthias Schwab; Michael Province; Michelle Whirl-Carrillo; W. Fraser Symmans; Howard L. McLeod; Mark J. Ratain; Hitoshi Zembutsu; Andrea Gaedigk; Ron H. van Schaik; James N. Ingle; Kelly E. Caudle; Teri E. Klein

doi:10.1002/cpt.1007

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew P. Goetz, Katrin Sangkuhl, Henk Jan Guchelaar, Matthias Schwab, Michael Province, Michelle Whirl-Carrillo, W. Fraser Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron H. van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein

Research output: Contribution to journal › Article › peer-review

244 Scopus citations

Abstract

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

Original language	English
Pages (from-to)	770-777
Number of pages	8
Journal	Clinical pharmacology and therapeutics
Volume	103
Issue number	5
DOIs	https://doi.org/10.1002/cpt.1007
State	Published - May 2018

Access to Document

10.1002/cpt.1007

Cite this

Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M., Whirl-Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., Gaedigk, A., van Schaik, R. H., Ingle, J. N., Caudle, K. E., & Klein, T. E. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical pharmacology and therapeutics, 103(5), 770-777. https://doi.org/10.1002/cpt.1007

@article{d957002a0012487da9025ab31f3796a2,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy",

abstract = "Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.",

author = "Goetz, {Matthew P.} and Katrin Sangkuhl and Guchelaar, {Henk Jan} and Matthias Schwab and Michael Province and Michelle Whirl-Carrillo and Symmans, {W. Fraser} and McLeod, {Howard L.} and Ratain, {Mark J.} and Hitoshi Zembutsu and Andrea Gaedigk and {van Schaik}, {Ron H.} and Ingle, {James N.} and Caudle, {Kelly E.} and Klein, {Teri E.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics",

year = "2018",

month = may,

doi = "10.1002/cpt.1007",

language = "English",

volume = "103",

pages = "770--777",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

number = "5",

}

Goetz, MP, Sangkuhl, K, Guchelaar, HJ, Schwab, M, Province, M, Whirl-Carrillo, M, Symmans, WF, McLeod, HL, Ratain, MJ, Zembutsu, H, Gaedigk, A, van Schaik, RH, Ingle, JN, Caudle, KE & Klein, TE 2018, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy', Clinical pharmacology and therapeutics, vol. 103, no. 5, pp. 770-777. https://doi.org/10.1002/cpt.1007

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

AU - Goetz, Matthew P.

AU - Sangkuhl, Katrin

AU - Guchelaar, Henk Jan

AU - Schwab, Matthias

AU - Province, Michael

AU - Whirl-Carrillo, Michelle

AU - Symmans, W. Fraser

AU - McLeod, Howard L.

AU - Ratain, Mark J.

AU - Zembutsu, Hitoshi

AU - Gaedigk, Andrea

AU - van Schaik, Ron H.

AU - Ingle, James N.

AU - Caudle, Kelly E.

AU - Klein, Teri E.

PY - 2018/5

Y1 - 2018/5

N2 - Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

AB - Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

UR - http://www.scopus.com/inward/record.url?scp=85041238598&partnerID=8YFLogxK

U2 - 10.1002/cpt.1007

DO - 10.1002/cpt.1007

M3 - Article

C2 - 29385237

AN - SCOPUS:85041238598

SN - 0009-9236

VL - 103

SP - 770

EP - 777

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 5

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this